Different Forms of OMT as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea
Launched by REGION VÄSTERBOTTEN · Mar 18, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Introduction/Background
Snoring and obstructive sleep apnea (OSA) are common among the adult population; a mean of 22% and 17% of the women are affected. Obstructive sleep apnea is related to several negative health effects, such as sleepiness, hypertension, cardiovascular disease, and cognitive impairment. Continuous positive airway pressure (CPAP), oral appliances (OA), as well as oropharyngeal surgery in selected cases are available as a treatment for OSA. The same methods can be used for reducing snoring, but the cost for the devices is high, and the compliance tends to be low, althoug...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women with AHI 10 - 29 seeking for problems with snoring and obstructive sleep apnea, age 18 to 75.
- Exclusion Criteria:
- • Subjects with previous surgery of the soft palate, 9 \< AHI \> 29, smokers, New York Heart Association Functional Classification, NYHA ≥ 3. BMI \>34,9.
About Region Västerbotten
Region Västerbotten is a leading healthcare authority in northern Sweden, dedicated to advancing medical research and improving patient care through innovative clinical trials. As a sponsor, Region Västerbotten focuses on collaborating with academic institutions, industry partners, and healthcare professionals to facilitate groundbreaking studies that address critical health challenges. With a commitment to ethical standards and patient safety, the organization aims to contribute to the global body of medical knowledge while enhancing the quality of healthcare services in the region. Through its robust infrastructure and expertise, Region Västerbotten strives to drive scientific discovery and foster an environment of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lund, , Sweden
Köge, Sjaelland, Denmark
Lund, Skåne, Sweden
Umeå, Västerbotten, Sweden
Umeå, , Sweden
Patients applied
Trial Officials
Thorbjörn Holmlund, PhD
Principal Investigator
Region Västerbotten
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported